{
  "Study_ID": "TRSTMH_2018_Thapa",
  "First_Author": "Thapa, K.",
  "Year": "2018",
  "Country": "Ecuador",
  "Study_Design": "Randomized Controlled Trial",
  "Risk_of_Bias": "Low",
  "Diagnostic_Criteria": "CT/MRI showing active or transitional cysts",
  "Total_Sample_Size": "173",
  "Treatment_Group_N": "86",
  "Control_Group_N": "87",
  "Age_Mean_SD": "Not reported",
  "Male_Percentage": "Not reported",
  "Female_Percentage": "Not reported",
  "Other_Demographics": "Not specified",
  "Headache_Percentage": "71.7% at baseline",
  "Focal_Seizures_Percentage": "Not specified",
  "Other_Symptoms": "Memory loss/confusion, Anxiety/depression, GI symptoms, Vision problems, Limb weakness/gait disturbance",
  "Treatment_Type": "Albendazole + Prednisone",
  "Albendazole_Dose": "400 mg every 12h for 8 days",
  "Treatment_Duration_Days": "8",
  "Number_of_Cycles": "1",
  "Cycle_Interval_Days": "Not applicable",
  "Praziquantel_Dose": "Not used",
  "Corticosteroid_Type": "Prednisone 75 mg daily, tapered over 2 weeks",
  "Antiepileptic_Drug": "Not specified",
  "Follow_up_Duration_Months": "24",
  "Imaging_Schedule": "Baseline with follow-ups at months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, and 24",
  "Complete_Resolution_Percentage": "Not reported",
  "Partial_Resolution_Percentage": "Not reported",
  "No_Change_Percentage": "Not reported",
  "Seizure_Reduction_Percentage": "Not applicable",
  "Elevated_Liver_Enzymes_Percentage": "Not reported",
  "Other_AE": "Increased anxiety/depression (OR 1.87), reduced memory loss/confusion (OR 0.42)",
  "Comments": "Baseline symptoms included headaches (71.7%), GI symptoms (33.5%), limb weakness/gait disturbance (25.7%), anxiety/depression (17.3%), vision problems (17.4%), memory loss/confusion (15.8%). Headaches persisted in most cases over 24 months with similar frequency in both groups. Study focused on non-seizure outcomes; findings indicate decrease in memory/confusion with Albendazole and increase in anxiety/depression",
  "last_modified": "2024-10-31T12:59:17.025361"
}